Another approach for application is to use vaccines that are made from a gene-modified virus in order to kill MPNST tumors that are either unresectable or recurrent with NF1 mutation (Clinicaltrials.gov ID: NCT02700230). This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.